このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Ascletis Pharma 将来の成長

Future 基準チェック /06

Ascletis Pharmaの収益と利益はそれぞれ年間19%と9.3%減少すると予測されていますが、EPS は年間9.9% 減少すると予測されています。

主要情報

-9.3%

収益成長率

-9.9%

EPS成長率

Biotechs 収益成長	35.8%
収益成長率	-19.0%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	17 Apr 2024

今後の成長に関する最新情報

Recent updates

We're Not Very Worried About Ascletis Pharma's (HKG:1672) Cash Burn Rate

Dec 19

We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely

Aug 23

What You Need To Know About The Ascletis Pharma Inc. (HKG:1672) Analyst Downgrade Today

Nov 03

Companies Like Ascletis Pharma (HKG:1672) Can Afford To Invest In Growth

Oct 13

Need To Know: Analysts Just Made A Substantial Cut To Their Ascletis Pharma Inc. (HKG:1672) Estimates

Aug 24

Here's Why We're Not Too Worried About Ascletis Pharma's (HKG:1672) Cash Burn Situation

May 19

Ascletis Pharma Inc.'s (HKG:1672) Sole Analyst Just Made A Dazzling Upgrade To Their Forecasts

Mar 27

We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely

Feb 08

業績と収益の成長予測

SEHK:1672 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	51	-182	N/A	N/A	2
12/31/2025	N/A	-242	N/A	-163	3
12/31/2024	N/A	-219	N/A	-152	3
12/31/2023	57	-145	-163	-144	N/A
9/30/2023	59	-194	-169	-157	N/A
6/30/2023	62	-243	-115	-111	N/A
3/31/2023	58	-279	-136	-127	N/A
12/31/2022	54	-315	-217	-202	N/A
9/30/2022	66	-246	-198	-182	N/A
6/30/2022	79	-176	-179	-161	N/A
3/31/2022	78	-188	-167	-154	N/A
12/31/2021	77	-199	-154	-147	N/A
9/30/2021	58	-234	-172	-150	N/A
6/30/2021	40	-269	-190	-153	N/A
3/31/2021	37	-239	-157	-119	N/A
12/31/2020	35	-209	-124	-85	N/A
9/30/2020	82	-155	-86	-56	N/A
6/30/2020	130	-100	-47	-28	N/A
3/31/2020	152	-98	-75	-51	N/A
12/31/2019	173	-96	-103	-74	N/A
9/30/2019	150	-92	-130	-91	N/A
6/30/2019	127	-89	-157	-107	N/A
3/31/2019	153	-43	-146	-83	N/A
12/31/2018	166	-7	-157	-97	N/A
9/30/2018	154	-5	-172	-134	N/A
6/30/2018	142	-2	-188	-171	N/A
3/31/2018	91	-40	-243	-210	N/A
12/31/2017	53	-54	-234	-198	N/A
12/31/2016	33	-27	N/A	-12	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 1672今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 1672今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: 1672今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 1672来年は収益がないと予測されています。

高い収益成長: 1672来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 1672の自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Ascletis Pharma 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Consensus revenue estimates decrease by 19%, EPS upgraded

Consensus revenue estimates decrease by 22%, EPS upgraded

Forecast breakeven date moved forward to 2023

Consensus revenue estimates decrease by 12%

Consensus revenue estimates increase by 27%

Forecast breakeven date moved forward to 2023

Recent updates

Ascletis Pharma Inc. Announces Presentation Designing Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy- Confirmed Mash At EASL Congress 2024

Ascletis Pharma Inc., Annual General Meeting, May 23, 2024

Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ascletis Pharma Inc. Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting

Ascletis Pharma Inc. to Report Fiscal Year 2023 Results on Mar 25, 2024

Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase III Clinical Trial of Asc40 (Denifanstat) for Treatment of Acne

New major risk - Revenue and earnings growth

Ascletis Pharma Inc. Announces Positive Interim Results from 52-Week Phase Ii Clinical Trial of Once-Daily Asc41 Tablet in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis

We're Not Very Worried About Ascletis Pharma's (HKG:1672) Cash Burn Rate

Ascletis Pharma Inc. Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne

First half 2023 earnings: EPS exceeds analyst expectations

Ascletis Pharma Inc. Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure

Ascletis Pharma Inc. Announces Completion of Enrollment of 120 Patients in the Phase Ii Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

Consensus revenue estimates decrease by 19%, EPS upgraded

We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely

First half 2023 earnings released: CN¥0.015 loss per share (vs CN¥0.081 loss in 1H 2022)

New major risk - Revenue and earnings growth

Ascletis Pharma Inc. to Report Q2, 2023 Results on Aug 21, 2023

Ascletis Pharma Inc. Announces Completion of Patient Enrollment for Phase Ii Clinical Trial of Asc42, an Fxr Agonist, for Primary Biliary Cholangitis

New minor risk - Profitability

Consensus revenue estimates decrease by 22%, EPS upgraded

Ascletis Pharma Inc., Annual General Meeting, Jun 29, 2023

Ascletis Pharma Inc. Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection

Full year 2022 earnings: EPS and revenues miss analyst expectations

Forecast breakeven date moved forward to 2023

Consensus revenue estimates decrease by 12%

Ascletis Pharma Inc. Announces Oral Presentation at APASL Annual Meeting 2023 Demonstrates ASC22, a Subcutaneous PD-L1 Antibody, Can Achieve Functional Cure of Chronic Hepatitis B

Consensus revenue estimates increase by 27%

Forecast breakeven date moved forward to 2023

Ascletis Pharma Announces U.S. FDA Approval of Conducting Phase IIA Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection

Ascletis Announces IND Approval of Oral Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by China Nmpa

Ascletis Pharma Inc. Doses 4 Healthy Subjects of the First Cohort in Multiple-Dose Escalation Phase I Clinical Trial of Oral 3CLpro Inhibitor ASC11 for COVID-19

Viking Therapeutics, Inc. Files Complaints Against Ascletis Pharma Inc

Ascletis Announces Positive Phase I Clinical Results of Oral Rdrp Inhibitor Asc10 for Covid-19

Ascletis Pharma Inc. Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA

Ascletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor Asc40 for Acne

Ascletis Pharma Inc. Announces IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19 Accepted by China NMPA

Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for Covid-19 by U.S. FDA

Ascletis Pharma Inc. Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors by China NMPA

Ascletis Pharma Inc. Announces IND Approval of Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by U.S. FDA

Insufficient new directors

Ascletis Pharma Inc. Announces Poster Presentation of Phase I, Single-Dose Study of ASC43F for NASH at AASLD Annual Meeting 2022

What You Need To Know About The Ascletis Pharma Inc. (HKG:1672) Analyst Downgrade Today

Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19

Consensus revenue estimates fall by 19%

Ascletis Pharma Inc. Announces U.S. IND Filing of Oral Antiviral ASC10 for Monkeypox Indication

Companies Like Ascletis Pharma (HKG:1672) Can Afford To Invest In Growth

Ascletis Announces Dosing of 24 Healthy Subjects of the First 3 Cohorts in Multiple-Dose Escalation Phase I Clinical Trial of Oral RdRp Inhibitor ASC10 for COVID-19

Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase Ii Clinical Trial of Thrß Agonist Asc41 for 52-Week Treatment of Liver Biopsy-Proven Nash

Ascletis Announces Dosing of the First Patient in the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure

Ascletis Pharma Inc. Announces Clinical Study of PD-L1 antibody ASC22

Consensus revenue estimates fall by 13%

Need To Know: Analysts Just Made A Substantial Cut To Their Ascletis Pharma Inc. (HKG:1672) Estimates

First half 2022 earnings released: CN¥0.081 loss per share (vs CN¥0.10 loss in 1H 2021)

Ascletis Pharma Inc. Announces Change of Company Secretary

Ascletis Announces IND Approval of Oral RdRp Inhibitor ASC10 for COVID-19 by China NMPA

Vascletis Pharma Inc. Announces First Subject Dosed in the U.S. Drug-Drug Interaction Study of FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis

Ascletis Announces First Patient Dosed in the U.S. Phase I Clinical Trial of Oral PD-L1 Small Molecule Inhibitor Prodrug ASC61 for Treatment of Advanced Solid Tumors

Ascletis Announces IND Filing of Oral RdRp Inhibitor ASC10 for COVID-19 Accepted by China NMPA

Ascletis Announces FDA Clearance of Oral RdRp Inhibitor ASC10 to Conduct a Randomized, Placebo Controlled Phase Ib Study in Mild-to-Moderate COVID-19 Patients

Ascletis Pharma Inc. to Report First Half, 2022 Results on Aug 22, 2022

Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19

Ascletis Pharma Inc. Announces Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection

Ascletis Pharma Inc. Announces First Subject Dosed in the Phase II Clinical Trial of ASC22 (Envafolimab) for Immune Restoration/ Functional Cure of HIV-1 Infection

Ascletis Pharma Inc. Announces the Latest Phase Iib Clinical Trial Results of Subcutaneous Pd-L1 Antibody Asc22 (Envafolimab) in Patients with Chronic Hepatitis B (Chb) At an Oral Parallel Session of the International Liver Congress™ 2022

Ascletis Pharma Inc. Announces Oral Presentation on Updates from Phase IIb Clinical Trial of ASC22, a Subcutaneous PD-L1 Antibody for Functional Cure of Chronic Hepatitis B at EASL ILC 2022

Ascletis Pharma Inc. Appoints John P. Gargiulo as Chief Business Officer

Ascletis Pharma Inc., Annual General Meeting, Jun 16, 2022